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HIV-infected individuals are at higher risk for cardiovascular disease (CVD) compared to 
the general population [1]. This increased risk is exponentially greater in older HIV-infected 
persons [1]. Given that the survival rate of the HIV-infected population is nearing that of the 
general population with the widespread use of highly effective antiretroviral treatment 
(ART), there is growing concern that the risk of CVD will be magnified several-fold as this 
aging group continues to increase in prevalence. Thus, therapies to address this risk for CVD 
in older patients are needed.
Oxidative stress denotes inappropriately increased intracellular generation of reactive 
oxygen species (ROS) which in turn damages cellular lipid membranes and organelles with 
subsequent cellular dysfunction and death. Chronic oxidative stress has been associated with 
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the aging process through accumulated cellular damage and senescence and thus is a strong 
candidate for the mechanism by which HIV may lead to premature aging [2].
It remains unknown if pharmacologically reducing ROS will reduce oxidative stress and 
improve CVD risk in HIV-infected patients already receiving ART.
Glutathione is the primary intracellular antioxidant responsible for controlling oxidative 
stress [3] and appears to be depleted in those with HIV infection [4]. N-acetylcysteine 
(NAC) is a sulfur hydroxyl compound that replenishes intracellular cysteine, which is 
required for glutathione regeneration. NAC has been used safely in several small trials of 
HIV-infected patients not yet on ART [5-7], and in most, but not all, replenished glutathione 
stores and reduced oxidative stress measures. But trials are needed to determine if NAC can 
similarly reduce oxidative stress in ART-treated, virologically-suppressed patients.
We performed a prospective, randomized, double-blind, three-arm, parallel-group, placebo-
controlled, 8-week pilot trial in HIV-infected patients at least 50 years old and receiving 
virologically suppressive ART (ClinicalTrials.gov NCT01962961) to evaluate the potential 
efficacy and safety of PharmaNAC, a commercially available product considered to be a 
supplement and not requiring FDA approval (http://www.pharmanac.com/; BioAdvantex 
Pharma Inc.). PharmaNAC contains 900mg of NAC as an effervescent tablet without the 
sulfur odor associated with other forms of NAC. Participants were equally randomized to 
one of the following three study arms: PharmaNAC 900mg twice daily, PharmaNAC 
1800mg twice daily, or matching placebos. Randomization with varying block sizes was 
implemented at the Entry Visit with stratification for current smoking.
The primary objectives of this study were to compare the 8-week changes in levels of 
circulating malondialdehyde (MDA) and F2-isoprostane, both measures of oxidative stress, 
and flow-mediated dilation (FMD) of the brachial artery as a physiologic measure of 
endothelial function. The red blood cell oxidative stress markers GSH (reduced glutathione), 
GSSG (oxidized glutathione), and GSH:GSSG ratios were measured on the first 15 
participants enrolled into the trial (7, 6, and 2 in the PharmaNAC 900bid arm, the 
PharmaNAC 1800mg bid arm, and the placebo arm, respectively).
HIV-infected patients of age ≥ 50 years and receiving ART for at least six months and 
resulting in an HIV-1 RNA level <75 copies/mL at study screening were eligible. Primary 
exclusion criteria diagnosed vascular disease (including congestive heart failure), history of 
portal hypertension or hepatic cirrhosis, diagnosis of asthma or COPD, previous receipt of 
stavudine or didanosine for more than 7 days, current receipt of daily vitamins C or E, and 
alcohol use more than the equivalent of 8 oz. of wine daily for 7 days prior to screening. 
This study was approved by the Indiana University Institutional Review Board; all 
participants provided written, informed consent.
For all analyses, an intention-to-treat (ITT) approach was used. Statistical significance was 
considered if two-sided p-values were less than 5%. As a pilot study, no formal sample size 
justification was performed and enrollment was based primarily on availability of study 
resources. Multivariable linear regression models were constructed in those who had paired 
data available to evaluate changes in the oxidative stress markers (MDA, F2-isoprostanes, 
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GSH, GSSG, GSH:GSSG) and FMD; these models included study arm assignment and 
baseline values of each marker (as there were non-significant, but appreciable, imbalances of 
these markers at baseline) to determine their effects on changes at Week 8.
Twenty-six patients screened for inclusion into this trial; two of these failed screening due to 
disqualifying laboratory values with the remaining 24 participants enrolled and randomized 
between December 2013 and May 2014. Of these 24, 9 were randomized to PharmaNAC 
900 twice daily, 8 were randomized to PharmaNAC 1800mg twice daily, and 7 were 
randomized to placebo. The baseline characteristics of the study arms are shown in 
Supplemental Table 1. One participant in the PharmaNAC 1800mg bid arm stopped study 
participation due to the detection of anal cancer not thought to be due to study participation. 
Another participant was discontinued due to the development of a severe rash that was later 
determined to be due to scabies and not thought to be due to study participation. The 
numbers of adverse events were similar amongst the three study arms without any 
appreciable differences in specific symptoms, laboratory toxicities, or diagnoses.
Results of models incorporating baseline values of the endpoints of interest on the changes 
from Entry to Week 8 are shown in Table 1. We found that baseline levels of F2-
isoprostanes, FMD, and GSSG were significantly associated with their respective changes at 
Week 8. We also found that treatment with PharmaNAC at each dosage compared to placebo 
led to non-significant, but appreciable, decreases in F2-isoprostane levels, increases in GSH, 
reductions in GSSG, and increases in GSH:GSSG at Week 8. However, there were no 
appreciable differences in the changes in MDA with PharmaNAC at either dosage compared 
to placebo at Week 8. Of note, additional adjustments for race and sex in these models did 
not appreciably affect these results.
In this randomized, placebo-controlled, pilot trial, we found that use of PharmaNAC at either 
1800mg twice daily or 900mg twice daily for 8 weeks was generally well-tolerated in HIV-
infected adults at least 50 years old and who were receiving virologically suppressive ART. 
We found that that the levels of reduced glutathione levels in red blood cells increased 
substantially while the levels of red blood cell oxidized glutathione levels decreased 
substantially, thereby leading to overall non-significantly increased ratios of GSH:GSSG 
with both doses of PharmaNAC compared to placebo. This suggests that this preparation of 
NAC may enhance the ability of cells to neutralize higher levels of ROS. In fact, we did find 
that F2-isoprostane levels, but not MDA levels, decreased with both PharmaNAC dosages 
compared to placebo. And in turn, FMD levels increased in both PhamaNAC arms compared 
to placebo, suggesting an improvement in endothelial function with NAC. In this initial pilot 
study, the small sample sizes likely precluded finding statistically significant differences 
between either of the two doses of PharmaNAC and placebo for the primary endpoints of 
oxidative stress and endothelial function. As we believe that these changes are clinically 
relevant, a more definitive, longer-term trial with adequate power appears to be justified.
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Refer to Web version on PubMed Central for supplementary material.
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Table 1
Week 8 changes in FMD and oxidative stress markers after adjusting for baseline values.
Outcome Effect Point estimate P-value
F2-isoprostanes, pg/mL
1800mg bid vs. placebo −6.87 0.51
900mg bid vs. placebo −7.87 0.44
Baseline value −0.82 <.0001
Malondialdehyde,μM
1800mg bid vs. placebo 0.017 0.98
900mg bid vs. placebo 0.21 0.75
Baseline value 0.17 0.65
Flow-mediated dilation, %
1800mg bid vs. placebo 0.75 0.44
900mg bid vs. placebo 0.83 0.38
Baseline value −0.56 0.0015
GSH (reduced glutathione),μM
1800mg bid vs. placebo 177.60 0.67
900mg bid vs. placebo 409.75 0.38
Baseline value −0.11 0.85
GSSG (oxidized glutathione),μM
1800mg bid vs. placebo −22.49 0.62
900mg bid vs. placebo −11.69 0.80
Baseline value −0.76 0.049
GSH:GSSG
1800mg bid vs. placebo 7.90 0.71
900mg bid vs. placebo 23.40 0.23
Baseline value −0.53 0.36
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